Ignite Creation Date:
2025-12-24 @ 8:02 PM
Ignite Modification Date:
2026-03-08 @ 11:21 PM
Study NCT ID:
NCT03099304
Status:
COMPLETED
Last Update Posted:
2022-11-17
First Post:
2017-03-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2021-10-06', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D014820', 'term': 'Vitiligo'}], 'ancestors': [{'id': 'D017496', 'term': 'Hypopigmentation'}, {'id': 'D010859', 'term': 'Pigmentation Disorders'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'medinfo@incyte.com', 'phone': '1.855.463.3463', 'title': 'Incyte Corporation Call Center (US)', 'organization': 'Incyte'}, 'certainAgreement': {'otherDetails': 'Clinical Study Agreement', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Up to 180 weeks (156-week treatment period plus 6-month follow-up period)', 'description': '157 participants received 1 of 4 doses of ruxolitinib cream or vehicle during the 24-week, DB period. After the DB period, 11 stayed on 0.15% QD and 42 were re-randomized to 1 of 3 higher groups. All others remained on the same treatment regimen through Week 52. 47 randomized to the 1.5% BID arm during Week 52 stayed during the OL period and 83 from the 3 lower dose arms (0.15% QD, 0.5% QD, and 1.5% QD) crossed over to the 1.5% BID arm during the OL period, totaling 130 at risk at data cut-off.', 'eventGroups': [{'id': 'EG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.', 'otherNumAtRisk': 32, 'deathsNumAtRisk': 32, 'otherNumAffected': 14, 'seriousNumAtRisk': 32, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Ruxolitinib Cream 0.15% Once Daily (QD)', 'description': 'All participants who received at least one dose of ruxolitinib cream 0.15% QD (in the 52-week combined vehicle-controlled and continued double-blind periods).', 'otherNumAtRisk': 31, 'deathsNumAtRisk': 31, 'otherNumAffected': 19, 'seriousNumAtRisk': 31, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'All participants who received at least one dose of ruxolitinib cream 0.5% QD. Treatment was received by participants for 52 weeks in the combined vehicle-controlled and continued double-blind periods, and by those participants who were randomized to the vehicle group or were randomized to ruxolitinib cream 0.15% QD and did not achieve 25% improvement in F-VASI score at Week 24 and crossed over to 0.5% QD for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]).', 'otherNumAtRisk': 45, 'deathsNumAtRisk': 45, 'otherNumAffected': 23, 'seriousNumAtRisk': 45, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'All participants who received at least one dose of ruxolitinib cream 1.5% QD. Treatment was received by participants for 52 weeks in the combined vehicle-controlled and continued double-blind periods, and by those participants who were randomized to the vehicle group or were randomized to ruxolitinib cream 0.15% QD and did not achieve 25% improvement in F-VASI score at Week 24 and crossed over to 1.5% QD for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]).', 'otherNumAtRisk': 44, 'deathsNumAtRisk': 44, 'otherNumAffected': 20, 'seriousNumAtRisk': 44, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'All participants who received at least one dose of ruxolitinib cream 1.5% BID. Treatment was received by (1) participants randomized to ruxolitinib cream 1.5% BID through Week 156, (2) participants who were randomized to the vehicle group or were randomized to ruxolitinib cream 0.15% QD and did not achieve 25% improvement in F-VASI score at Week 24 and crossed over to 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), and (3) participants who were (a) randomized to the vehicle group, (b) to ruxolitinib cream 0.15% QD and achieved 25% improvement in F-VASI score at Week 24, (c) to ruxolitinib cream 0.5% QD, and (d) to ruxolitinib cream 1.5% QD who crossed over to 1.5% BID during the open-label extension period.', 'otherNumAtRisk': 130, 'deathsNumAtRisk': 130, 'otherNumAffected': 45, 'seriousNumAtRisk': 130, 'deathsNumAffected': 0, 'seriousNumAffected': 4}], 'otherEvents': [{'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Acne', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 7, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 12, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 14, 'numAffected': 12}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Application site erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Application site exfoliation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Application site pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 8, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Dermatitis contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 5, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 8, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 11, 'numAffected': 9}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Skin exfoliation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Skin laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 12, 'numAffected': 8}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}], 'seriousEvents': [{'term': 'Breast cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Cholecystitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Coronary artery occlusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Oesophageal achalasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Subdural haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 31, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 44, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 130, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index Score (F-VASI50) Compared With Participants Treated With Vehicle at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.1', 'groupId': 'OG000'}, {'value': '32.3', 'groupId': 'OG001'}, {'value': '25.8', 'groupId': 'OG002'}, {'value': '50.0', 'groupId': 'OG003'}, {'value': '45.5', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.0057', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '13.79', 'ciLowerLimit': '1.73', 'ciUpperLimit': '640.85', 'pValueComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0243', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '10.30', 'ciLowerLimit': '1.24', 'ciUpperLimit': '487.28', 'pValueComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '28.48', 'ciLowerLimit': '3.74', 'ciUpperLimit': '1305.2', 'pValueComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '24.66', 'ciLowerLimit': '3.28', 'ciUpperLimit': '1121.4', 'pValueComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline; Week 24', 'description': "An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \\[BSA\\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) Population: all randomized participants. Treatment groups were to be defined according to the treatment assignment at the time of randomization regardless of the actual ruxolitinib cream or vehicle cream participants might have applied during their participation in the study. Missing post-Baseline values were considered as not having achieved responses for visits up to Week 52.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants Who Achieved a Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) of Clear or Almost Clear", 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '3.2', 'groupId': 'OG001'}, {'value': '9.7', 'groupId': 'OG002'}, {'value': '13.3', 'groupId': 'OG003'}, {'value': '9.1', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.4936', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.03', 'ciLowerLimit': '0.05', 'pValueComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'ciUpperLimitComment': 'The upper limit of the confidence interval was not estimatable because there were too few participants with a response of clear or almost clear.'}, {'pValue': '0.1140', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.16', 'ciLowerLimit': '0.62', 'pValueComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'ciUpperLimitComment': 'The upper limit of the confidence interval was not estimatable because there were too few participants with a response of clear or almost clear.'}, {'pValue': '0.0501', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.10', 'ciLowerLimit': '1.00', 'pValueComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'ciUpperLimitComment': 'The upper limit of the confidence interval was not estimatable because there were too few participants with a response of clear or almost clear.'}, {'pValue': '0.1257', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.89', 'ciLowerLimit': '0.58', 'pValueComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'ciUpperLimitComment': 'The upper limit of the confidence interval was not estimatable because there were too few participants with a response of clear or almost clear.'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Missing post-Baseline values were considered as not having achieved F-PhGVA response for visits up to Week 24.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Achieved a ≥ 50% Improvement From Baseline in Full Body Assessment of Vitiligo Area and Severity Index (T-VASI) at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '50', 'groupId': 'OG000'}, {'value': '21.4', 'groupId': 'OG001'}, {'value': '16.7', 'groupId': 'OG002'}, {'value': '15.4', 'groupId': 'OG003'}, {'value': '25.8', 'groupId': 'OG004'}, {'value': '30.0', 'groupId': 'OG005'}, {'value': '36.4', 'groupId': 'OG006'}]}]}], 'analyses': [{'pValue': '0.9794', 'groupIds': ['OG004', 'OG005'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.19', 'ciLowerLimit': '0.33', 'ciUpperLimit': '4.33', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).'}, {'pValue': '0.4893', 'groupIds': ['OG004', 'OG006'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.69', 'ciLowerLimit': '0.51', 'ciUpperLimit': '5.86', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline; Week 52', 'description': 'T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Missing post-Baseline values were considered as not having achieved responses for visits up to Week 52. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Dose Response on Percentage Change From Baseline in F-VASI', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'timeFrame': 'up to 156 weeks', 'reportingStatus': 'POSTED', 'populationDescription': 'Based on the data for percentage change from Baseline in F-VASI and T-VASI scores during the treatment periods, the Emax model was not appropriate; therefore, the dose responses were not assessed.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Grade 3 or Higher TEAE up to Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Any TEAE', 'categories': [{'measurements': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}, {'value': '22', 'groupId': 'OG003'}, {'value': '20', 'groupId': 'OG004'}]}]}, {'title': 'Any Grade 3 or higher TEAE', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'up to 24 weeks', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population: all participants who applied at least 1 dose of study drug. Treatment groups for this population were to be determined according to the actual treatment the participant received on Day 1.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE up to Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Any TEAE', 'categories': [{'measurements': [{'value': '26', 'groupId': 'OG004'}, {'value': '23', 'groupId': 'OG005'}, {'value': '23', 'groupId': 'OG006'}]}]}, {'title': 'Any Grade 3 or higher TEAE', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'up to 52 weeks', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Treatment groups for this population were to be determined according to the actual treatment the participant received on Day 1. Analysis from Day 1 to Week 52 was conducted in participants randomized to receive ruxolitinib cream 0.5% QD, ruxolitinib cream 1.5% QD, or ruxolitinib cream 1.5% BID during the vehicle-controlled period (Day 1 to Week 24).'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 24 to Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Any TEAE', 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}]}, {'title': 'Any Grade 3 or higher TEAE', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 24 to Week 52', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Treatment groups for this population were to be determined according to the actual treatment the participant received on Day 1. Analysis was conducted in participants who were randomized to ruxolitinib cream 0.15% QD and vehicle groups in the vehicle-controlled period (Day 1 to Week 24) and then had a dose in the continued double-blind period (Week 24 to Week 52).'}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Applied Ruxolitinib 1.5% Cream BID Throughout Study Participation With Any TEAE and Any Grade 3 or Higher TEAE', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Any TEAE', 'categories': [{'measurements': [{'value': '26', 'groupId': 'OG006'}]}]}, {'title': 'Any Grade 3 or higher TEAE', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'up to Week 156', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Treatment groups for this population were to be determined according to the actual treatment the participant received on Day 1. Analysis was only conducted in participants who received ruxolitinib cream 1.5% BID on Day 1.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 52 to Week 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Cross-over', 'description': 'Participants who were randomized to vehicle cream BID or to ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) on Day 1 of the double-blind, vehicle-controlled treatment period and received ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}], 'classes': [{'title': 'Any TEAE', 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '25', 'groupId': 'OG003'}]}]}, {'title': 'Any Grade 3 or higher TEAE', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 52 to Week 156', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Open-label Evaluable Population: all randomized participants who received at least 1 dose of study drug in the Open-label Period'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in F-VASI Score at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.05', 'spread': '0.11', 'groupId': 'OG000'}, {'value': '-0.39', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '-0.35', 'spread': '0.11', 'groupId': 'OG002'}, {'value': '-0.63', 'spread': '0.11', 'groupId': 'OG003'}, {'value': '-0.46', 'spread': '0.10', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.0056', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least squares mean (LSM) difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.44', 'ciLowerLimit': '-0.75', 'ciUpperLimit': '-0.13', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '0.0095', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.40', 'ciLowerLimit': '-0.70', 'ciUpperLimit': '-0.10', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.68', 'ciLowerLimit': '-0.99', 'ciUpperLimit': '-0.37', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '0.0011', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.51', 'ciLowerLimit': '-0.80', 'ciUpperLimit': '-0.21', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline; Week 24', 'description': "F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.", 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Mixed-model for Repeated Measures (MMRM) model for post-Baseline measures: (response variable = treatment + stratification factor \\[age ≤30 versus \\>30\\] + visit + treatment\\*visit). All post-Baseline visits up to Week 24 were included in the model.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in F-VASI Score at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.77', 'spread': '0.387', 'groupId': 'OG000'}, {'value': '1.21', 'spread': '0.891', 'groupId': 'OG001'}, {'value': '1.66', 'spread': '0.993', 'groupId': 'OG002'}, {'value': '1.14', 'spread': '0.714', 'groupId': 'OG003'}, {'value': '1.22', 'spread': '0.705', 'groupId': 'OG004'}, {'value': '1.45', 'spread': '0.980', 'groupId': 'OG005'}, {'value': '1.26', 'spread': '0.808', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.59', 'spread': '0.459', 'groupId': 'OG000'}, {'value': '-0.67', 'spread': '0.811', 'groupId': 'OG001'}, {'value': '-1.02', 'spread': '1.058', 'groupId': 'OG002'}, {'value': '-0.58', 'spread': '0.783', 'groupId': 'OG003'}, {'value': '-0.58', 'spread': '0.578', 'groupId': 'OG004'}, {'value': '-0.74', 'spread': '0.797', 'groupId': 'OG005'}, {'value': '-0.76', 'spread': '0.610', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.66', 'spread': '0.444', 'groupId': 'OG000'}, {'value': '-0.97', 'spread': '1.061', 'groupId': 'OG001'}, {'value': '-1.79', 'spread': '1.077', 'groupId': 'OG002'}, {'value': '-0.87', 'spread': '0.903', 'groupId': 'OG003'}, {'value': '-1.00', 'spread': '0.697', 'groupId': 'OG004'}, {'value': '-1.17', 'spread': '0.961', 'groupId': 'OG005'}, {'value': '-0.99', 'spread': '0.817', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.66', 'spread': '0.124', 'groupId': 'OG000'}, {'value': '-0.98', 'spread': '1.092', 'groupId': 'OG001'}, {'value': '-1.40', 'spread': '1.018', 'groupId': 'OG002'}, {'value': '-0.65', 'spread': '0.557', 'groupId': 'OG003'}, {'value': '-0.71', 'spread': '0.490', 'groupId': 'OG004'}, {'value': '-0.95', 'spread': '0.949', 'groupId': 'OG005'}, {'value': '-1.23', 'spread': '0.887', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.", 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in F-VASI Score at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.02', 'spread': '7.23', 'groupId': 'OG000'}, {'value': '-30.69', 'spread': '7.39', 'groupId': 'OG001'}, {'value': '-29.10', 'spread': '6.93', 'groupId': 'OG002'}, {'value': '-40.00', 'spread': '7.39', 'groupId': 'OG003'}, {'value': '-37.78', 'spread': '6.89', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.0005', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-36.71', 'ciLowerLimit': '-57.15', 'ciUpperLimit': '-16.27', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.34', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '0.0006', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-35.12', 'ciLowerLimit': '-54.91', 'ciUpperLimit': '-15.33', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.01', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-46.02', 'ciLowerLimit': '-66.47', 'ciUpperLimit': '-25.57', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.35', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-43.80', 'ciLowerLimit': '-63.52', 'ciUpperLimit': '-24.07', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '9.98', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline; Week 24', 'description': "F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.", 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. MMRM model for post-Baseline measures: (response variable = treatment + stratification factor \\[age ≤30 versus \\>30\\] + visit + treatment\\*visit). All post-Baseline visits up to Week 24 were included in the model.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in F-VASI Score at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-72.21', 'spread': '26.837', 'groupId': 'OG000'}, {'value': '-50.60', 'spread': '34.954', 'groupId': 'OG001'}, {'value': '-52.43', 'spread': '36.412', 'groupId': 'OG002'}, {'value': '-40.79', 'spread': '37.082', 'groupId': 'OG003'}, {'value': '-45.54', 'spread': '35.148', 'groupId': 'OG004'}, {'value': '-55.63', 'spread': '42.823', 'groupId': 'OG005'}, {'value': '-57.34', 'spread': '50.115', 'groupId': 'OG006'}]}]}, {'title': 'Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-77.67', 'spread': '22.974', 'groupId': 'OG000'}, {'value': '-71.12', 'spread': '31.087', 'groupId': 'OG001'}, {'value': '-82.87', 'spread': '32.756', 'groupId': 'OG002'}, {'value': '-60.28', 'spread': '64.708', 'groupId': 'OG003'}, {'value': '-74.89', 'spread': '25.524', 'groupId': 'OG004'}, {'value': '-77.76', 'spread': '24.086', 'groupId': 'OG005'}, {'value': '-78.78', 'spread': '28.400', 'groupId': 'OG006'}]}]}, {'title': 'Week 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-87.95', 'spread': '8.207', 'groupId': 'OG000'}, {'value': '-66.83', 'spread': '45.106', 'groupId': 'OG001'}, {'value': '-91.25', 'spread': '14.631', 'groupId': 'OG002'}, {'value': '-59.16', 'spread': '42.627', 'groupId': 'OG003'}, {'value': '-76.25', 'spread': '20.126', 'groupId': 'OG004'}, {'value': '-76.76', 'spread': '23.924', 'groupId': 'OG005'}, {'value': '-89.52', 'spread': '14.899', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.", 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Achieved an F-VASI50 at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '90.0', 'groupId': 'OG000'}, {'value': '64.3', 'groupId': 'OG001'}, {'value': '50.0', 'groupId': 'OG002'}, {'value': '38.5', 'groupId': 'OG003'}, {'value': '45.2', 'groupId': 'OG004'}, {'value': '43.3', 'groupId': 'OG005'}, {'value': '57.6', 'groupId': 'OG006'}]}]}, {'title': 'Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '88.9', 'groupId': 'OG000'}, {'value': '87.5', 'groupId': 'OG001'}, {'value': '88.9', 'groupId': 'OG002'}, {'value': '77.8', 'groupId': 'OG003'}, {'value': '78.9', 'groupId': 'OG004'}, {'value': '83.3', 'groupId': 'OG005'}, {'value': '89.5', 'groupId': 'OG006'}]}]}, {'title': 'Week 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '75.0', 'groupId': 'OG001'}, {'value': '100.0', 'groupId': 'OG002'}, {'value': '60.0', 'groupId': 'OG003'}, {'value': '87.5', 'groupId': 'OG004'}, {'value': '87.5', 'groupId': 'OG005'}, {'value': '100.0', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in F-BSA Repigmentation at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.49', 'spread': '32.028', 'groupId': 'OG000'}, {'value': '-19.82', 'spread': '24.928', 'groupId': 'OG001'}, {'value': '-17.55', 'spread': '25.453', 'groupId': 'OG002'}, {'value': '-19.53', 'spread': '38.612', 'groupId': 'OG003'}, {'value': '-27.76', 'spread': '30.996', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Week 24', 'description': 'F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant\'s entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant\'s thumb was considered as 0.1% BSA. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in F-BSA Repigmentation at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-55.18', 'spread': '36.091', 'groupId': 'OG000'}, {'value': '-37.94', 'spread': '32.569', 'groupId': 'OG001'}, {'value': '-33.39', 'spread': '40.095', 'groupId': 'OG002'}, {'value': '-15.64', 'spread': '29.733', 'groupId': 'OG003'}, {'value': '-34.67', 'spread': '37.769', 'groupId': 'OG004'}, {'value': '-38.37', 'spread': '38.660', 'groupId': 'OG005'}, {'value': '-44.29', 'spread': '35.253', 'groupId': 'OG006'}]}]}, {'title': 'Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-42.86', 'spread': '31.282', 'groupId': 'OG000'}, {'value': '-67.61', 'spread': '29.683', 'groupId': 'OG001'}, {'value': '-76.57', 'spread': '31.260', 'groupId': 'OG002'}, {'value': '-45.65', 'spread': '59.599', 'groupId': 'OG003'}, {'value': '-54.49', 'spread': '34.411', 'groupId': 'OG004'}, {'value': '-63.56', 'spread': '28.543', 'groupId': 'OG005'}, {'value': '-59.49', 'spread': '38.186', 'groupId': 'OG006'}]}]}, {'title': 'Week 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-33.04', 'spread': '6.313', 'groupId': 'OG000'}, {'value': '-59.17', 'spread': '40.586', 'groupId': 'OG001'}, {'value': '-90.50', 'spread': '16.240', 'groupId': 'OG002'}, {'value': '-16.89', 'spread': '56.706', 'groupId': 'OG003'}, {'value': '-55.80', 'spread': '33.310', 'groupId': 'OG004'}, {'value': '-59.58', 'spread': '27.106', 'groupId': 'OG005'}, {'value': '-72.58', 'spread': '31.024', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': 'F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant\'s entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant\'s thumb was considered as 0.1% BSA. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in T-BSA Repigmentation at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.35', 'spread': '8.314', 'groupId': 'OG000'}, {'value': '-13.97', 'spread': '25.396', 'groupId': 'OG001'}, {'value': '-10.83', 'spread': '15.646', 'groupId': 'OG002'}, {'value': '-17.19', 'spread': '22.490', 'groupId': 'OG003'}, {'value': '-13.60', 'spread': '20.443', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Week 24', 'description': "T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.", 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in T-BSA Repigmentation at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-39.53', 'spread': '32.599', 'groupId': 'OG000'}, {'value': '-8.72', 'spread': '26.010', 'groupId': 'OG001'}, {'value': '-2.72', 'spread': '23.014', 'groupId': 'OG002'}, {'value': '-8.73', 'spread': '21.630', 'groupId': 'OG003'}, {'value': '-15.13', 'spread': '21.296', 'groupId': 'OG004'}, {'value': '-27.33', 'spread': '27.568', 'groupId': 'OG005'}, {'value': '-27.59', 'spread': '26.770', 'groupId': 'OG006'}]}]}, {'title': 'Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-42.42', 'spread': '32.208', 'groupId': 'OG000'}, {'value': '-30.49', 'spread': '36.289', 'groupId': 'OG001'}, {'value': '-30.08', 'spread': '30.717', 'groupId': 'OG002'}, {'value': '-21.08', 'spread': '30.323', 'groupId': 'OG003'}, {'value': '-33.19', 'spread': '30.127', 'groupId': 'OG004'}, {'value': '-33.94', 'spread': '26.573', 'groupId': 'OG005'}, {'value': '-32.46', 'spread': '33.190', 'groupId': 'OG006'}]}]}, {'title': 'Week 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-59.44', 'spread': '51.920', 'groupId': 'OG000'}, {'value': '-46.58', 'spread': '30.723', 'groupId': 'OG001'}, {'value': '-34.93', 'spread': '35.391', 'groupId': 'OG002'}, {'value': '-37.95', 'spread': '23.651', 'groupId': 'OG003'}, {'value': '-29.59', 'spread': '32.261', 'groupId': 'OG004'}, {'value': '-10.55', 'spread': '53.863', 'groupId': 'OG005'}, {'value': '-46.88', 'spread': '19.304', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.", 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in T-VASI Score at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.57', 'spread': '0.92', 'groupId': 'OG000'}, {'value': '-2.27', 'spread': '0.94', 'groupId': 'OG001'}, {'value': '-2.18', 'spread': '0.88', 'groupId': 'OG002'}, {'value': '-4.51', 'spread': '0.94', 'groupId': 'OG003'}, {'value': '-3.52', 'spread': '0.87', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.0326', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.84', 'ciLowerLimit': '-5.44', 'ciUpperLimit': '-0.24', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.32', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '0.0333', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.74', 'ciLowerLimit': '-5.26', 'ciUpperLimit': '-0.22', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.28', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '0.0002', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.08', 'ciLowerLimit': '-7.68', 'ciUpperLimit': '-2.48', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.31', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '0.0016', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.08', 'ciLowerLimit': '-6.59', 'ciUpperLimit': '-1.57', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.27', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline; Week 24', 'description': "T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline (BL) was calculated as the post-BL value minus the BL value.", 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. MMRM model for post-Baseline measures: (response variable = treatment + stratification factor \\[age ≤30 versus \\>30\\] + visit + treatment\\*visit). All post-Baseline visits up to Week 24 were included in the model.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in T-VASI Score at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '9.56', 'spread': '7.090', 'groupId': 'OG000'}, {'value': '13.47', 'spread': '11.655', 'groupId': 'OG001'}, {'value': '22.82', 'spread': '19.187', 'groupId': 'OG002'}, {'value': '20.75', 'spread': '15.973', 'groupId': 'OG003'}, {'value': '18.43', 'spread': '15.363', 'groupId': 'OG004'}, {'value': '20.55', 'spread': '18.488', 'groupId': 'OG005'}, {'value': '16.94', 'spread': '14.256', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-4.59', 'spread': '4.979', 'groupId': 'OG000'}, {'value': '-2.88', 'spread': '2.934', 'groupId': 'OG001'}, {'value': '-3.21', 'spread': '4.536', 'groupId': 'OG002'}, {'value': '-3.88', 'spread': '5.642', 'groupId': 'OG003'}, {'value': '-3.97', 'spread': '6.284', 'groupId': 'OG004'}, {'value': '-7.37', 'spread': '7.403', 'groupId': 'OG005'}, {'value': '-6.14', 'spread': '7.442', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-6.02', 'spread': '5.476', 'groupId': 'OG000'}, {'value': '-5.32', 'spread': '5.615', 'groupId': 'OG001'}, {'value': '-9.71', 'spread': '9.398', 'groupId': 'OG002'}, {'value': '-6.62', 'spread': '7.054', 'groupId': 'OG003'}, {'value': '-7.19', 'spread': '9.079', 'groupId': 'OG004'}, {'value': '-10.77', 'spread': '9.658', 'groupId': 'OG005'}, {'value': '-7.74', 'spread': '5.927', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-2.33', 'spread': '0.269', 'groupId': 'OG000'}, {'value': '-10.23', 'spread': '13.533', 'groupId': 'OG001'}, {'value': '-11.31', 'spread': '12.185', 'groupId': 'OG002'}, {'value': '-7.82', 'spread': '4.209', 'groupId': 'OG003'}, {'value': '-4.72', 'spread': '3.622', 'groupId': 'OG004'}, {'value': '-7.02', 'spread': '9.577', 'groupId': 'OG005'}, {'value': '-8.77', 'spread': '4.996', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value.", 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in T-VASI Score at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.65', 'spread': '4.89', 'groupId': 'OG000'}, {'value': '-20.88', 'spread': '5.00', 'groupId': 'OG001'}, {'value': '-15.82', 'spread': '4.69', 'groupId': 'OG002'}, {'value': '-27.16', 'spread': '4.99', 'groupId': 'OG003'}, {'value': '-22.91', 'spread': '4.65', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.0010', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-23.53', 'ciLowerLimit': '-37.35', 'ciUpperLimit': '-9.71', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.99', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '0.0072', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-18.47', 'ciLowerLimit': '-31.86', 'ciUpperLimit': '-5.08', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.77', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-29.81', 'ciLowerLimit': '-43.61', 'ciUpperLimit': '-16.00', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.98', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}, {'pValue': '0.0002', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LSM difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-25.56', 'ciLowerLimit': '-38.89', 'ciUpperLimit': '-12.22', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.75', 'estimateComment': 'LSM difference = treatment minus vehicle', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Treatment comparisons were performed using the log-rank test stratified by randomization stratification factor.'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline; Week 24', 'description': "T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).", 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100. MMRM model for post-Baseline measures: (response variable = treatment + stratification factor \\[age ≤30 versus \\>30\\] + visit + treatment\\*visit). All post-Baseline visits up to Week 24 were included in the model.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in T-VASI Score at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-50.71', 'spread': '33.310', 'groupId': 'OG000'}, {'value': '-25.12', 'spread': '31.556', 'groupId': 'OG001'}, {'value': '-19.75', 'spread': '26.484', 'groupId': 'OG002'}, {'value': '-20.00', 'spread': '29.264', 'groupId': 'OG003'}, {'value': '-24.67', 'spread': '29.649', 'groupId': 'OG004'}, {'value': '-41.90', 'spread': '35.865', 'groupId': 'OG005'}, {'value': '-41.67', 'spread': '26.451', 'groupId': 'OG006'}]}]}, {'title': 'Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-60.96', 'spread': '32.259', 'groupId': 'OG000'}, {'value': '-49.35', 'spread': '39.319', 'groupId': 'OG001'}, {'value': '-49.07', 'spread': '29.091', 'groupId': 'OG002'}, {'value': '-38.70', 'spread': '38.663', 'groupId': 'OG003'}, {'value': '-46.44', 'spread': '31.668', 'groupId': 'OG004'}, {'value': '-52.14', 'spread': '33.559', 'groupId': 'OG005'}, {'value': '-50.03', 'spread': '26.905', 'groupId': 'OG006'}]}]}, {'title': 'Week 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-71.10', 'spread': '31.448', 'groupId': 'OG000'}, {'value': '-59.33', 'spread': '40.055', 'groupId': 'OG001'}, {'value': '-47.31', 'spread': '34.610', 'groupId': 'OG002'}, {'value': '-49.96', 'spread': '27.555', 'groupId': 'OG003'}, {'value': '-44.69', 'spread': '30.718', 'groupId': 'OG004'}, {'value': '-14.97', 'spread': '58.982', 'groupId': 'OG005'}, {'value': '-62.80', 'spread': '20.904', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).", 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in Vitiligo European Task Force (VETF) Scale Scores at Week 24: Total Spreading', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.78', 'spread': '2.166', 'groupId': 'OG000'}, {'value': '2.74', 'spread': '2.422', 'groupId': 'OG001'}, {'value': '1.84', 'spread': '2.238', 'groupId': 'OG002'}, {'value': '1.83', 'spread': '2.102', 'groupId': 'OG003'}, {'value': '1.21', 'spread': '2.233', 'groupId': 'OG004'}]}]}, {'title': 'Change from Baseline at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.12', 'spread': '2.566', 'groupId': 'OG000'}, {'value': '-3.15', 'spread': '3.246', 'groupId': 'OG001'}, {'value': '-3.27', 'spread': '3.532', 'groupId': 'OG002'}, {'value': '-3.12', 'spread': '2.971', 'groupId': 'OG003'}, {'value': '-3.58', 'spread': '3.042', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Spreading', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '2.73', 'spread': '2.328', 'groupId': 'OG000'}, {'value': '2.43', 'spread': '2.277', 'groupId': 'OG001'}, {'value': '1.21', 'spread': '2.607', 'groupId': 'OG002'}, {'value': '2.21', 'spread': '1.968', 'groupId': 'OG003'}, {'value': '1.84', 'spread': '2.238', 'groupId': 'OG004'}, {'value': '1.83', 'spread': '2.102', 'groupId': 'OG005'}, {'value': '1.21', 'spread': '2.233', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-4.70', 'spread': '3.683', 'groupId': 'OG000'}, {'value': '-4.14', 'spread': '3.592', 'groupId': 'OG001'}, {'value': '-3.83', 'spread': '3.538', 'groupId': 'OG002'}, {'value': '-3.85', 'spread': '3.211', 'groupId': 'OG003'}, {'value': '-3.48', 'spread': '3.622', 'groupId': 'OG004'}, {'value': '-3.86', 'spread': '3.395', 'groupId': 'OG005'}, {'value': '-3.66', 'spread': '2.742', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-5.00', 'spread': '4.153', 'groupId': 'OG000'}, {'value': '-4.25', 'spread': '3.196', 'groupId': 'OG001'}, {'value': '-4.22', 'spread': '3.667', 'groupId': 'OG002'}, {'value': '-5.11', 'spread': '3.371', 'groupId': 'OG003'}, {'value': '-3.16', 'spread': '3.516', 'groupId': 'OG004'}, {'value': '-3.56', 'spread': '3.034', 'groupId': 'OG005'}, {'value': '-3.26', 'spread': '3.034', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '22.81', 'spread': '20.843', 'groupId': 'OG000'}, {'value': '16.26', 'spread': '11.006', 'groupId': 'OG001'}, {'value': '22.35', 'spread': '20.878', 'groupId': 'OG002'}, {'value': '24.63', 'spread': '22.236', 'groupId': 'OG003'}, {'value': '20.79', 'spread': '16.192', 'groupId': 'OG004'}]}]}, {'title': 'Change from Baseline at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.38', 'spread': '1.329', 'groupId': 'OG000'}, {'value': '-1.08', 'spread': '3.867', 'groupId': 'OG001'}, {'value': '-2.43', 'spread': '4.797', 'groupId': 'OG002'}, {'value': '-3.27', 'spread': '6.744', 'groupId': 'OG003'}, {'value': '-2.71', 'spread': '4.591', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '9.18', 'spread': '6.509', 'groupId': 'OG000'}, {'value': '16.43', 'spread': '11.979', 'groupId': 'OG001'}, {'value': '24.50', 'spread': '21.841', 'groupId': 'OG002'}, {'value': '24.50', 'spread': '18.798', 'groupId': 'OG003'}, {'value': '22.35', 'spread': '20.878', 'groupId': 'OG004'}, {'value': '24.63', 'spread': '22.236', 'groupId': 'OG005'}, {'value': '20.79', 'spread': '16.192', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-3.10', 'spread': '3.814', 'groupId': 'OG000'}, {'value': '-1.86', 'spread': '2.905', 'groupId': 'OG001'}, {'value': '-1.17', 'spread': '3.486', 'groupId': 'OG002'}, {'value': '-1.92', 'spread': '6.211', 'groupId': 'OG003'}, {'value': '-3.93', 'spread': '7.191', 'groupId': 'OG004'}, {'value': '-5.71', 'spread': '8.463', 'groupId': 'OG005'}, {'value': '-4.48', 'spread': '6.127', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-3.89', 'spread': '4.226', 'groupId': 'OG000'}, {'value': '-4.75', 'spread': '5.994', 'groupId': 'OG001'}, {'value': '-5.11', 'spread': '4.226', 'groupId': 'OG002'}, {'value': '-4.44', 'spread': '7.367', 'groupId': 'OG003'}, {'value': '-8.00', 'spread': '10.392', 'groupId': 'OG004'}, {'value': '-7.78', 'spread': '8.695', 'groupId': 'OG005'}, {'value': '-6.26', 'spread': '6.682', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.61', 'spread': '9.497', 'groupId': 'OG000'}, {'value': '-10.61', 'spread': '29.408', 'groupId': 'OG001'}, {'value': '-13.87', 'spread': '25.296', 'groupId': 'OG002'}, {'value': '-14.09', 'spread': '20.321', 'groupId': 'OG003'}, {'value': '-13.10', 'spread': '17.605', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-32.01', 'spread': '35.629', 'groupId': 'OG000'}, {'value': '-7.39', 'spread': '21.571', 'groupId': 'OG001'}, {'value': '-10.57', 'spread': '22.300', 'groupId': 'OG002'}, {'value': '-7.13', 'spread': '25.967', 'groupId': 'OG003'}, {'value': '-19.73', 'spread': '30.730', 'groupId': 'OG004'}, {'value': '-22.36', 'spread': '23.593', 'groupId': 'OG005'}, {'value': '-25.41', 'spread': '24.049', 'groupId': 'OG006'}]}]}, {'title': 'Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-39.30', 'spread': '37.071', 'groupId': 'OG000'}, {'value': '-23.05', 'spread': '29.233', 'groupId': 'OG001'}, {'value': '-34.03', 'spread': '27.992', 'groupId': 'OG002'}, {'value': '-18.49', 'spread': '36.527', 'groupId': 'OG003'}, {'value': '-35.55', 'spread': '34.039', 'groupId': 'OG004'}, {'value': '-30.40', 'spread': '22.940', 'groupId': 'OG005'}, {'value': '-29.19', 'spread': '39.767', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in VETF Scale Scores at Week 24: Total Staging', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '10.03', 'spread': '3.515', 'groupId': 'OG000'}, {'value': '9.29', 'spread': '3.013', 'groupId': 'OG001'}, {'value': '10.03', 'spread': '3.945', 'groupId': 'OG002'}, {'value': '9.97', 'spread': '3.000', 'groupId': 'OG003'}, {'value': '8.42', 'spread': '3.464', 'groupId': 'OG004'}]}]}, {'title': 'Change from Baseline at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.15', 'spread': '3.184', 'groupId': 'OG000'}, {'value': '-1.62', 'spread': '2.282', 'groupId': 'OG001'}, {'value': '-1.57', 'spread': '2.687', 'groupId': 'OG002'}, {'value': '-1.96', 'spread': '3.561', 'groupId': 'OG003'}, {'value': '-0.74', 'spread': '2.633', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '8.64', 'spread': '2.908', 'groupId': 'OG000'}, {'value': '8.43', 'spread': '2.901', 'groupId': 'OG001'}, {'value': '11.29', 'spread': '2.128', 'groupId': 'OG002'}, {'value': '10.07', 'spread': '3.668', 'groupId': 'OG003'}, {'value': '10.03', 'spread': '3.945', 'groupId': 'OG004'}, {'value': '9.97', 'spread': '3.000', 'groupId': 'OG005'}, {'value': '8.42', 'spread': '3.464', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-3.10', 'spread': '3.247', 'groupId': 'OG000'}, {'value': '-1.29', 'spread': '2.301', 'groupId': 'OG001'}, {'value': '-2.17', 'spread': '3.157', 'groupId': 'OG002'}, {'value': '-2.62', 'spread': '2.844', 'groupId': 'OG003'}, {'value': '-2.41', 'spread': '3.030', 'groupId': 'OG004'}, {'value': '-3.48', 'spread': '2.960', 'groupId': 'OG005'}, {'value': '-1.38', 'spread': '2.555', 'groupId': 'OG006'}]}]}, {'title': 'Change from Baseline at Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-3.44', 'spread': '3.358', 'groupId': 'OG000'}, {'value': '-2.75', 'spread': '3.694', 'groupId': 'OG001'}, {'value': '-2.22', 'spread': '3.866', 'groupId': 'OG002'}, {'value': '-2.89', 'spread': '1.537', 'groupId': 'OG003'}, {'value': '-2.84', 'spread': '2.754', 'groupId': 'OG004'}, {'value': '-4.00', 'spread': '3.049', 'groupId': 'OG005'}, {'value': '-1.68', 'spread': '2.730', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Staging', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-7.58', 'spread': '18.740', 'groupId': 'OG000'}, {'value': '-17.52', 'spread': '22.267', 'groupId': 'OG001'}, {'value': '-13.55', 'spread': '21.200', 'groupId': 'OG002'}, {'value': '-17.00', 'spread': '31.798', 'groupId': 'OG003'}, {'value': '-4.46', 'spread': '38.916', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-33.48', 'spread': '25.022', 'groupId': 'OG000'}, {'value': '-12.70', 'spread': '24.012', 'groupId': 'OG001'}, {'value': '-17.31', 'spread': '22.623', 'groupId': 'OG002'}, {'value': '-23.88', 'spread': '19.262', 'groupId': 'OG003'}, {'value': '-21.45', 'spread': '24.571', 'groupId': 'OG004'}, {'value': '-30.00', 'spread': '22.563', 'groupId': 'OG005'}, {'value': '-12.99', 'spread': '29.585', 'groupId': 'OG006'}]}]}, {'title': 'Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-37.20', 'spread': '29.132', 'groupId': 'OG000'}, {'value': '-24.29', 'spread': '30.439', 'groupId': 'OG001'}, {'value': '-16.55', 'spread': '27.268', 'groupId': 'OG002'}, {'value': '-32.06', 'spread': '12.311', 'groupId': 'OG003'}, {'value': '-27.76', 'spread': '23.202', 'groupId': 'OG004'}, {'value': '-35.20', 'spread': '23.904', 'groupId': 'OG005'}, {'value': '-14.09', 'spread': '26.969', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants in Each Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) Category at Week 24", 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': '0', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}]}]}, {'title': '1', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '3.2', 'groupId': 'OG001'}, {'value': '9.7', 'groupId': 'OG002'}, {'value': '13.3', 'groupId': 'OG003'}, {'value': '9.1', 'groupId': 'OG004'}]}]}, {'title': '2', 'categories': [{'measurements': [{'value': '6.3', 'groupId': 'OG000'}, {'value': '16.1', 'groupId': 'OG001'}, {'value': '16.1', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '27.3', 'groupId': 'OG004'}]}]}, {'title': '3', 'categories': [{'measurements': [{'value': '40.6', 'groupId': 'OG000'}, {'value': '64.5', 'groupId': 'OG001'}, {'value': '61.3', 'groupId': 'OG002'}, {'value': '36.7', 'groupId': 'OG003'}, {'value': '54.5', 'groupId': 'OG004'}]}]}, {'title': '4', 'categories': [{'measurements': [{'value': '34.4', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '9.7', 'groupId': 'OG002'}, {'value': '16.7', 'groupId': 'OG003'}, {'value': '3.0', 'groupId': 'OG004'}]}]}, {'title': 'Missing at the visit', 'categories': [{'measurements': [{'value': '18.8', 'groupId': 'OG000'}, {'value': '16.1', 'groupId': 'OG001'}, {'value': '3.2', 'groupId': 'OG002'}, {'value': '13.3', 'groupId': 'OG003'}, {'value': '6.1', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.4936', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.03', 'ciLowerLimit': '0.05', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'ciUpperLimitComment': 'The upper limit of the confidence interval was not estimatable because there were too few participants with a response of clear or almost clear.'}, {'pValue': '0.1140', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.16', 'ciLowerLimit': '0.62', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'ciUpperLimitComment': 'The upper limit of the confidence interval was not estimatable because there were too few participants with a response of clear or almost clear.'}, {'pValue': '0.0501', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.10', 'ciLowerLimit': '1.00', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'ciUpperLimitComment': 'The upper limit of the confidence interval was not estimatable because there were too few participants with a response of clear or almost clear.'}, {'pValue': '0.1257', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.89', 'ciLowerLimit': '0.58', 'statisticalMethod': 'exact logistic regression', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'The exact logistic regression model includes treatment and stratification factor (age ≤30 versus \\>30).', 'ciUpperLimitComment': 'The upper limit of the confidence interval was not estimatable because there were too few participants with a response of clear or almost clear.'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Missing post-Baseline values were considered as not having achieved F-PhGVA response for visits up to Week 24.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants in Each Facial Assessment of the PhGVA (F-PhGVA) Category at Weeks 52, 104 and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '6.9', 'groupId': 'OG004'}, {'value': '4.8', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '14.3', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '7.7', 'groupId': 'OG003'}, {'value': '10.3', 'groupId': 'OG004'}, {'value': '14.3', 'groupId': 'OG005'}, {'value': '24.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '60.0', 'groupId': 'OG000'}, {'value': '7.1', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}, {'value': '46.2', 'groupId': 'OG003'}, {'value': '17.2', 'groupId': 'OG004'}, {'value': '28.6', 'groupId': 'OG005'}, {'value': '37.9', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '71.4', 'groupId': 'OG001'}, {'value': '50.0', 'groupId': 'OG002'}, {'value': '46.2', 'groupId': 'OG003'}, {'value': '55.2', 'groupId': 'OG004'}, {'value': '42.9', 'groupId': 'OG005'}, {'value': '31.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '7.1', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '10.3', 'groupId': 'OG004'}, {'value': '9.5', 'groupId': 'OG005'}, {'value': '6.9', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '11.1', 'groupId': 'OG002'}, {'value': '11.1', 'groupId': 'OG003'}, {'value': '5.3', 'groupId': 'OG004'}, {'value': '11.1', 'groupId': 'OG005'}, {'value': '15.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '55.6', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}, {'value': '22.2', 'groupId': 'OG003'}, {'value': '31.6', 'groupId': 'OG004'}, {'value': '33.3', 'groupId': 'OG005'}, {'value': '31.6', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}, {'value': '22.2', 'groupId': 'OG003'}, {'value': '36.8', 'groupId': 'OG004'}, {'value': '27.8', 'groupId': 'OG005'}, {'value': '26.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '11.1', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '11.1', 'groupId': 'OG002'}, {'value': '44.4', 'groupId': 'OG003'}, {'value': '26.3', 'groupId': 'OG004'}, {'value': '27.8', 'groupId': 'OG005'}, {'value': '21.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '11.1', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '5.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '60.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '25.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '33.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '60.0', 'groupId': 'OG003'}, {'value': '12.5', 'groupId': 'OG004'}, {'value': '37.5', 'groupId': 'OG005'}, {'value': '55.6', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '50.0', 'groupId': 'OG004'}, {'value': '25.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '12.5', 'groupId': 'OG004'}, {'value': '37.5', 'groupId': 'OG005'}, {'value': '11.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 52, 104, and 156', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': '0', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}]}]}, {'title': '1', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '3.3', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '3.2', 'groupId': 'OG004'}]}]}, {'title': '2', 'categories': [{'measurements': [{'value': '11.5', 'groupId': 'OG000'}, {'value': '23.1', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '23.1', 'groupId': 'OG003'}, {'value': '35.5', 'groupId': 'OG004'}]}]}, {'title': '3', 'categories': [{'measurements': [{'value': '57.7', 'groupId': 'OG000'}, {'value': '76.9', 'groupId': 'OG001'}, {'value': '70.0', 'groupId': 'OG002'}, {'value': '61.5', 'groupId': 'OG003'}, {'value': '58.1', 'groupId': 'OG004'}]}]}, {'title': '4', 'categories': [{'measurements': [{'value': '30.8', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '6.7', 'groupId': 'OG002'}, {'value': '15.4', 'groupId': 'OG003'}, {'value': '3.2', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Weeks 52, 104 and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '10.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '10.3', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '6.9', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '35.7', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '7.7', 'groupId': 'OG003'}, {'value': '13.8', 'groupId': 'OG004'}, {'value': '28.6', 'groupId': 'OG005'}, {'value': '55.2', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '40.0', 'groupId': 'OG000'}, {'value': '57.1', 'groupId': 'OG001'}, {'value': '83.3', 'groupId': 'OG002'}, {'value': '84.6', 'groupId': 'OG003'}, {'value': '69.0', 'groupId': 'OG004'}, {'value': '61.9', 'groupId': 'OG005'}, {'value': '31.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '7.1', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '7.7', 'groupId': 'OG003'}, {'value': '6.9', 'groupId': 'OG004'}, {'value': '9.5', 'groupId': 'OG005'}, {'value': '6.9', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '11.1', 'groupId': 'OG002'}, {'value': '11.1', 'groupId': 'OG003'}, {'value': '5.3', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '77.8', 'groupId': 'OG000'}, {'value': '37.5', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}, {'value': '33.3', 'groupId': 'OG003'}, {'value': '68.4', 'groupId': 'OG004'}, {'value': '55.6', 'groupId': 'OG005'}, {'value': '63.2', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '22.2', 'groupId': 'OG000'}, {'value': '37.5', 'groupId': 'OG001'}, {'value': '44.4', 'groupId': 'OG002'}, {'value': '55.6', 'groupId': 'OG003'}, {'value': '26.3', 'groupId': 'OG004'}, {'value': '27.8', 'groupId': 'OG005'}, {'value': '36.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '11.1', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '16.7', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '25.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '11.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '60.0', 'groupId': 'OG003'}, {'value': '50.0', 'groupId': 'OG004'}, {'value': '62.5', 'groupId': 'OG005'}, {'value': '66.7', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '60.0', 'groupId': 'OG002'}, {'value': '40.0', 'groupId': 'OG003'}, {'value': '25.0', 'groupId': 'OG004'}, {'value': '25.0', 'groupId': 'OG005'}, {'value': '22.2', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '12.5', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 52, 104, and 156', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants in Each Facial Assessment of the Patient's Global Vitiligo Assessment (F-PaGVA) Category at Week 24", 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': '0', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}]}]}, {'title': '1', 'categories': [{'measurements': [{'value': '9.4', 'groupId': 'OG000'}, {'value': '16.1', 'groupId': 'OG001'}, {'value': '12.9', 'groupId': 'OG002'}, {'value': '16.7', 'groupId': 'OG003'}, {'value': '33.3', 'groupId': 'OG004'}]}]}, {'title': '2', 'categories': [{'measurements': [{'value': '31.3', 'groupId': 'OG000'}, {'value': '38.7', 'groupId': 'OG001'}, {'value': '41.9', 'groupId': 'OG002'}, {'value': '40.0', 'groupId': 'OG003'}, {'value': '27.3', 'groupId': 'OG004'}]}]}, {'title': '3', 'categories': [{'measurements': [{'value': '28.1', 'groupId': 'OG000'}, {'value': '25.8', 'groupId': 'OG001'}, {'value': '35.5', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '24.2', 'groupId': 'OG004'}]}]}, {'title': '4', 'categories': [{'measurements': [{'value': '15.6', 'groupId': 'OG000'}, {'value': '3.2', 'groupId': 'OG001'}, {'value': '6.5', 'groupId': 'OG002'}, {'value': '10.0', 'groupId': 'OG003'}, {'value': '9.1', 'groupId': 'OG004'}]}]}, {'title': 'Missing at the visit', 'categories': [{'measurements': [{'value': '15.6', 'groupId': 'OG000'}, {'value': '16.1', 'groupId': 'OG001'}, {'value': '3.2', 'groupId': 'OG002'}, {'value': '13.3', 'groupId': 'OG003'}, {'value': '6.1', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Missing post-Baseline values were considered as not having achieved F-PaGVA response for visits up to Week 24.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants in Each Facial Assessment of the PaGVA (F-PaGVA) Category at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '3.4', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '21.4', 'groupId': 'OG001'}, {'value': '16.7', 'groupId': 'OG002'}, {'value': '30.8', 'groupId': 'OG003'}, {'value': '24.1', 'groupId': 'OG004'}, {'value': '30.0', 'groupId': 'OG005'}, {'value': '44.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '40.0', 'groupId': 'OG000'}, {'value': '28.6', 'groupId': 'OG001'}, {'value': '83.3', 'groupId': 'OG002'}, {'value': '46.2', 'groupId': 'OG003'}, {'value': '37.9', 'groupId': 'OG004'}, {'value': '30.0', 'groupId': 'OG005'}, {'value': '24.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '10.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '23.1', 'groupId': 'OG003'}, {'value': '34.5', 'groupId': 'OG004'}, {'value': '30.0', 'groupId': 'OG005'}, {'value': '20.7', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '3.4', 'groupId': 'OG004'}, {'value': '10.0', 'groupId': 'OG005'}, {'value': '6.9', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '5.3', 'groupId': 'OG004'}, {'value': '5.6', 'groupId': 'OG005'}, {'value': '5.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '66.7', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '22.2', 'groupId': 'OG002'}, {'value': '55.6', 'groupId': 'OG003'}, {'value': '42.1', 'groupId': 'OG004'}, {'value': '44.4', 'groupId': 'OG005'}, {'value': '36.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '22.2', 'groupId': 'OG000'}, {'value': '37.5', 'groupId': 'OG001'}, {'value': '55.6', 'groupId': 'OG002'}, {'value': '33.3', 'groupId': 'OG003'}, {'value': '36.8', 'groupId': 'OG004'}, {'value': '16.7', 'groupId': 'OG005'}, {'value': '47.4', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '11.1', 'groupId': 'OG000'}, {'value': '12.5', 'groupId': 'OG001'}, {'value': '22.0', 'groupId': 'OG002'}, {'value': '11.1', 'groupId': 'OG003'}, {'value': '15.8', 'groupId': 'OG004'}, {'value': '22.2', 'groupId': 'OG005'}, {'value': '5.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '11.1', 'groupId': 'OG005'}, {'value': '5.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '12.5', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '11.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '80.0', 'groupId': 'OG003'}, {'value': '37.5', 'groupId': 'OG004'}, {'value': '37.5', 'groupId': 'OG005'}, {'value': '44.4', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '80.0', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '50.0', 'groupId': 'OG004'}, {'value': '50.0', 'groupId': 'OG005'}, {'value': '22.2', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '11.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '12.5', 'groupId': 'OG005'}, {'value': '11.1', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 52, 104, and 156', 'description': 'The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': '0', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '3.2', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}]}]}, {'title': '1', 'categories': [{'measurements': [{'value': '6.3', 'groupId': 'OG000'}, {'value': '12.9', 'groupId': 'OG001'}, {'value': '9.7', 'groupId': 'OG002'}, {'value': '16.7', 'groupId': 'OG003'}, {'value': '15.2', 'groupId': 'OG004'}]}]}, {'title': '2', 'categories': [{'measurements': [{'value': '37.5', 'groupId': 'OG000'}, {'value': '35.5', 'groupId': 'OG001'}, {'value': '38.7', 'groupId': 'OG002'}, {'value': '33.3', 'groupId': 'OG003'}, {'value': '45.5', 'groupId': 'OG004'}]}]}, {'title': '3', 'categories': [{'measurements': [{'value': '31.3', 'groupId': 'OG000'}, {'value': '29.0', 'groupId': 'OG001'}, {'value': '35.5', 'groupId': 'OG002'}, {'value': '30.0', 'groupId': 'OG003'}, {'value': '21.2', 'groupId': 'OG004'}]}]}, {'title': '4', 'categories': [{'measurements': [{'value': '9.4', 'groupId': 'OG000'}, {'value': '6.5', 'groupId': 'OG001'}, {'value': '9.7', 'groupId': 'OG002'}, {'value': '6.7', 'groupId': 'OG003'}, {'value': '12.1', 'groupId': 'OG004'}]}]}, {'title': 'Missing at the visit', 'categories': [{'measurements': [{'value': '15.6', 'groupId': 'OG000'}, {'value': '16.1', 'groupId': 'OG001'}, {'value': '3.2', 'groupId': 'OG002'}, {'value': '13.3', 'groupId': 'OG003'}, {'value': '6.1', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Missing post-Baseline values were considered as not having achieved T-PaGVA response for visits up to Week 24.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '7.1', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '13.8', 'groupId': 'OG004'}, {'value': '25.0', 'groupId': 'OG005'}, {'value': '13.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '60.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '41.7', 'groupId': 'OG002'}, {'value': '69.2', 'groupId': 'OG003'}, {'value': '48.3', 'groupId': 'OG004'}, {'value': '40.0', 'groupId': 'OG005'}, {'value': '62.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '42.9', 'groupId': 'OG001'}, {'value': '50.0', 'groupId': 'OG002'}, {'value': '23.1', 'groupId': 'OG003'}, {'value': '27.6', 'groupId': 'OG004'}, {'value': '25.0', 'groupId': 'OG005'}, {'value': '10.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '20', 'groupId': 'OG004'}, {'value': '29', 'groupId': 'OG005'}, {'value': '20', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '7.7', 'groupId': 'OG003'}, {'value': '10.3', 'groupId': 'OG004'}, {'value': '10.0', 'groupId': 'OG005'}, {'value': '13.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '36.8', 'groupId': 'OG004'}, {'value': '22.2', 'groupId': 'OG005'}, {'value': '15.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '55.6', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '44.4', 'groupId': 'OG002'}, {'value': '77.8', 'groupId': 'OG003'}, {'value': '42.1', 'groupId': 'OG004'}, {'value': '44.4', 'groupId': 'OG005'}, {'value': '57.9', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '11.1', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '55.6', 'groupId': 'OG002'}, {'value': '22.2', 'groupId': 'OG003'}, {'value': '15.8', 'groupId': 'OG004'}, {'value': '16.7', 'groupId': 'OG005'}, {'value': '21.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '5.3', 'groupId': 'OG004'}, {'value': '16.7', 'groupId': 'OG005'}, {'value': '5.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '37.5', 'groupId': 'OG004'}, {'value': '12.5', 'groupId': 'OG005'}, {'value': '33.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '75.0', 'groupId': 'OG001'}, {'value': '40.0', 'groupId': 'OG002'}, {'value': '40.0', 'groupId': 'OG003'}, {'value': '50.0', 'groupId': 'OG004'}, {'value': '37.5', 'groupId': 'OG005'}, {'value': '55.6', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '40.0', 'groupId': 'OG002'}, {'value': '40.0', 'groupId': 'OG003'}, {'value': '12.5', 'groupId': 'OG004'}, {'value': '25.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '25.0', 'groupId': 'OG005'}, {'value': '11.1', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 52, 104, and 156', 'description': 'The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants in Each Patient Global Impression of Change for Vitiligo (PaGIC-V) Category at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': '1', 'categories': [{'measurements': [{'value': '7.4', 'groupId': 'OG000'}, {'value': '3.8', 'groupId': 'OG001'}, {'value': '6.7', 'groupId': 'OG002'}, {'value': '11.5', 'groupId': 'OG003'}, {'value': '6.5', 'groupId': 'OG004'}]}]}, {'title': '2', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '19.2', 'groupId': 'OG001'}, {'value': '13.3', 'groupId': 'OG002'}, {'value': '19.2', 'groupId': 'OG003'}, {'value': '22.6', 'groupId': 'OG004'}]}]}, {'title': '3', 'categories': [{'measurements': [{'value': '22.2', 'groupId': 'OG000'}, {'value': '34.6', 'groupId': 'OG001'}, {'value': '50.0', 'groupId': 'OG002'}, {'value': '53.8', 'groupId': 'OG003'}, {'value': '35.5', 'groupId': 'OG004'}]}]}, {'title': '4', 'categories': [{'measurements': [{'value': '37.0', 'groupId': 'OG000'}, {'value': '26.9', 'groupId': 'OG001'}, {'value': '23.3', 'groupId': 'OG002'}, {'value': '11.5', 'groupId': 'OG003'}, {'value': '25.8', 'groupId': 'OG004'}]}]}, {'title': '5', 'categories': [{'measurements': [{'value': '22.2', 'groupId': 'OG000'}, {'value': '11.5', 'groupId': 'OG001'}, {'value': '6.7', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '9.7', 'groupId': 'OG004'}]}]}, {'title': '6', 'categories': [{'measurements': [{'value': '11.1', 'groupId': 'OG000'}, {'value': '3.8', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '3.8', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}]}]}, {'title': '7', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline; Week 24', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants in Each PaGIC-V Category at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '7.1', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '7.7', 'groupId': 'OG003'}, {'value': '10.3', 'groupId': 'OG004'}, {'value': '4.8', 'groupId': 'OG005'}, {'value': '13.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '30.0', 'groupId': 'OG000'}, {'value': '14.3', 'groupId': 'OG001'}, {'value': '25.0', 'groupId': 'OG002'}, {'value': '23.1', 'groupId': 'OG003'}, {'value': '20.7', 'groupId': 'OG004'}, {'value': '47.6', 'groupId': 'OG005'}, {'value': '31.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '30.0', 'groupId': 'OG000'}, {'value': '42.9', 'groupId': 'OG001'}, {'value': '58.3', 'groupId': 'OG002'}, {'value': '46.2', 'groupId': 'OG003'}, {'value': '55.2', 'groupId': 'OG004'}, {'value': '38.1', 'groupId': 'OG005'}, {'value': '27.6', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '7.1', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '15.4', 'groupId': 'OG003'}, {'value': '6.9', 'groupId': 'OG004'}, {'value': '9.5', 'groupId': 'OG005'}, {'value': '20.7', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '28.6', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '7.7', 'groupId': 'OG003'}, {'value': '3.4', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '6.9', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '3.4', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 52, 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '11.1', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '11.1', 'groupId': 'OG002'}, {'value': '22.2', 'groupId': 'OG003'}, {'value': '10.5', 'groupId': 'OG004'}, {'value': '22.2', 'groupId': 'OG005'}, {'value': '21.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}, {'value': '12.5', 'groupId': 'OG001'}, {'value': '44.4', 'groupId': 'OG002'}, {'value': '33.3', 'groupId': 'OG003'}, {'value': '36.8', 'groupId': 'OG004'}, {'value': '38.9', 'groupId': 'OG005'}, {'value': '36.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '22.2', 'groupId': 'OG000'}, {'value': '62.5', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}, {'value': '22.2', 'groupId': 'OG003'}, {'value': '47.4', 'groupId': 'OG004'}, {'value': '22.2', 'groupId': 'OG005'}, {'value': '36.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '22.2', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '11.1', 'groupId': 'OG002'}, {'value': '22.2', 'groupId': 'OG003'}, {'value': '5.3', 'groupId': 'OG004'}, {'value': '11.1', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '11.1', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '5.3', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '5.6', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 104, 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '12.5', 'groupId': 'OG004'}, {'value': '12.5', 'groupId': 'OG005'}, {'value': '11.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '60.0', 'groupId': 'OG003'}, {'value': '25.0', 'groupId': 'OG004'}, {'value': '50.0', 'groupId': 'OG005'}, {'value': '77.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '40.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '62.5', 'groupId': 'OG004'}, {'value': '12.5', 'groupId': 'OG005'}, {'value': '11.1', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '12.5', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '12.5', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}, {'title': 'Week 156, 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'groupId': 'OG004'}, {'value': '0.0', 'groupId': 'OG005'}, {'value': '0.0', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.4', 'groupId': 'OG000'}, {'value': '23.1', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '30.8', 'groupId': 'OG003'}, {'value': '29.0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline; Week 24', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Weeks 52, 104, and 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}, {'value': '33', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods) in participants who saw greater than or equal to 25% improvement in F-VASI score at Week 24, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID', 'description': 'Participants who were randomized to the vehicle group and participants who were randomized to ruxolitinib cream 0.15% QD who did not achieve a 25% improvement in F-VASI score at Week 24 who crossed over to ruxolitinib cream 1.5% BID for 28 weeks (Week 24 to Week 52 \\[continued double-blind treatment period\\]), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 0.5% QD: 1.5% BID', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG005', 'title': 'Ruxolitinib Cream 1.5% QD: 1.5 % BID', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG006', 'title': 'Ruxolitinib Cream 1.5% BID: 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}, {'value': '29', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '30.0', 'groupId': 'OG000'}, {'value': '21.4', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}, {'value': '30.8', 'groupId': 'OG003'}, {'value': '31.0', 'groupId': 'OG004'}, {'value': '52.4', 'groupId': 'OG005'}, {'value': '44.8', 'groupId': 'OG006'}]}]}, {'title': 'Week 104', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}, {'value': '19', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '44.4', 'groupId': 'OG000'}, {'value': '37.5', 'groupId': 'OG001'}, {'value': '55.6', 'groupId': 'OG002'}, {'value': '55.6', 'groupId': 'OG003'}, {'value': '47.4', 'groupId': 'OG004'}, {'value': '61.1', 'groupId': 'OG005'}, {'value': '57.9', 'groupId': 'OG006'}]}]}, {'title': 'Week 156', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '9', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '40.0', 'groupId': 'OG002'}, {'value': '80.0', 'groupId': 'OG003'}, {'value': '37.5', 'groupId': 'OG004'}, {'value': '62.5', 'groupId': 'OG005'}, {'value': '88.9', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population. Only participants with available data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Time to Achieve an F-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the F-VASI50 Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'The median and the upper and lower limits of the confidence interval were not estimable because too few participants achieved an F-VASI50.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '197.0', 'comment': 'The upper limit of the confidence interval was not estimable because too few participants achieved an F-VASI50.', 'groupId': 'OG001', 'lowerLimit': '127.0', 'upperLimit': 'NA'}, {'value': '339.0', 'comment': 'The upper limit of the confidence interval was not estimable because too few participants achieved an F-VASI50.', 'groupId': 'OG002', 'lowerLimit': '195.0', 'upperLimit': 'NA'}, {'value': '172.0', 'groupId': 'OG003', 'lowerLimit': '127.0', 'upperLimit': '323.0'}, {'value': '170.0', 'comment': 'The upper limit of the confidence interval was not estimable because too few participants achieved an F-VASI50.', 'groupId': 'OG004', 'lowerLimit': '127.0', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'up to 52 weeks', 'description': "An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).", 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population'}, {'type': 'SECONDARY', 'title': 'Time to Achieve a T-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the T-VASI50 Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'The median and the upper and lower limits of the confidence interval were not estimable because too few participants achieved a T-VASI50.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper limit of the confidence interval were not estimable because too few participants achieved a T-VASI50.', 'groupId': 'OG001', 'lowerLimit': '204.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper limit of the confidence interval were not estimable because too few participants achieved a T-VASI50.', 'groupId': 'OG002', 'lowerLimit': '366.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper limit of the confidence interval were not estimable because too few participants achieved a T-VASI50.', 'groupId': 'OG003', 'lowerLimit': '192.0', 'upperLimit': 'NA'}, {'value': '376.0', 'comment': 'The upper limit of the confidence interval was not estimable because too few participants achieved a T-VASI50.', 'groupId': 'OG004', 'lowerLimit': '276.0', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'up to 52 weeks', 'description': 'A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI. T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population'}, {'type': 'SECONDARY', 'title': 'Time to Achieve an F-PhGVA of Clear or Almost Clear', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'The median and the upper and lower limits of the confidence interval were not estimable because too few participants achieved an F-PhGVA of clear or almost clear.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '372.0', 'comment': 'The upper limit of the confidence interval was not estimable because too few participants achieved an F-PhGVA of clear or almost clear.', 'groupId': 'OG001', 'lowerLimit': '274.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper limit of the confidence interval were not estimable because too few participants achieved an F-PhGVA of clear or almost clear.', 'groupId': 'OG002', 'lowerLimit': '369.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper and lower limits of the confidence interval were not estimable because too few participants achieved an F-PhGVA of clear or almost clear.', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper limit of the confidence interval were not estimable because too few participants achieved an F-PhGVA of clear or almost clear.', 'groupId': 'OG004', 'lowerLimit': '367.0', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'up to 52 weeks', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening. Time to achieve an F-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the F-PhGVA score.', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population'}, {'type': 'SECONDARY', 'title': 'Time to Achieve an T-PhGVA of Clear or Almost Clear', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'The median and the upper and lower limits of the confidence interval were not estimable because too few participants achieved a T-PhGVA of clear or almost clear.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '372.0', 'comment': 'The upper limit of the confidence interval was not estimable because too few participants achieved a T-PhGVA of clear or almost clear.', 'groupId': 'OG001', 'lowerLimit': '274.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper and lower limits of the confidence interval were not estimable because too few participants achieved a T-PhGVA of clear or almost clear.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper and lower limits of the confidence interval were not estimable because too few participants achieved a T-PhGVA of clear or almost clear.', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper limit of the confidence interval were not estimable because too few participants achieved a T-PhGVA of clear or almost clear.', 'groupId': 'OG004', 'lowerLimit': '369.0', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'up to 52 weeks', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening. Time to achieve a T-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the T-PhGVA score.', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population'}, {'type': 'SECONDARY', 'title': 'Time to Achieve a PaGIC-V of Very Much Improved or Much Improved', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'OG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'OG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'The median and the upper and lower limits of the confidence interval were not estimable because too few participants achieved a PaGIC-V of very much improved or much improved.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper limit of the confidence interval were not estimable because too few participants achieved a PaGIC-V of very much improved or much improved.', 'groupId': 'OG001', 'lowerLimit': '274.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'The median and the upper limit of the confidence interval were not estimable because too few participants achieved a PaGIC-V of very much improved or much improved.', 'groupId': 'OG002', 'lowerLimit': '290.0', 'upperLimit': 'NA'}, {'value': '282.0', 'comment': 'The upper limit of the confidence interval was not estimable because too few participants achieved a PaGIC-V of very much improved or much improved.', 'groupId': 'OG003', 'lowerLimit': '169.0', 'upperLimit': 'NA'}, {'value': '281.0', 'comment': 'The upper limit of the confidence interval was not estimable because too few participants achieved a PaGIC-V of very much improved or much improved.', 'groupId': 'OG004', 'lowerLimit': '178.0', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'up to 52 weeks', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse. Time to achieve a PaGIC-V response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the PaGIC-V score.', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'FG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'FG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'FG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'FG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'FG005', 'title': 'Cross-over', 'description': 'Participants who were randomized to vehicle cream BID or to ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) on Day 1 of the double-blind, vehicle-controlled treatment period and received ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}], 'periods': [{'title': 'DB Period: Day 1 to Week 24', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '32'}, {'groupId': 'FG001', 'numSubjects': '31'}, {'groupId': 'FG002', 'numSubjects': '31'}, {'groupId': 'FG003', 'numSubjects': '30'}, {'groupId': 'FG004', 'numSubjects': '33'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '27'}, {'groupId': 'FG001', 'numSubjects': '26'}, {'groupId': 'FG002', 'numSubjects': '30'}, {'groupId': 'FG003', 'numSubjects': '26'}, {'groupId': 'FG004', 'numSubjects': '30'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '3'}, {'groupId': 'FG005', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Reason not specified', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}, {'title': 'DB Period: Weeks 24 to 52', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'Vehicle cream was not used after Week 24. After the 24-week DB period, participants who met criteria were re-randomized to 1 of the 3 higher active blinded treatment groups.', 'groupId': 'FG000', 'numSubjects': '0'}, {'comment': 'These participants continued on the initial 0.15% QD treatment.', 'groupId': 'FG001', 'numSubjects': '11'}, {'comment': 'Total participants included those initially randomized to 0.5% QD and those re-randomized from vehicle cream and 0.15% QD to 0.5% QD.', 'groupId': 'FG002', 'numSubjects': '45'}, {'comment': 'Total participants included those initially randomized to 1.5% QD and those re-randomized from vehicle cream and 0.15% QD to 1.5% QD.', 'groupId': 'FG003', 'numSubjects': '44'}, {'comment': 'Total participants included those initially randomized to 1.5% BID and those re-randomized from vehicle cream and 0.15% QD to 1.5% BID', 'groupId': 'FG004', 'numSubjects': '47'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '10'}, {'groupId': 'FG002', 'numSubjects': '43'}, {'groupId': 'FG003', 'numSubjects': '37'}, {'groupId': 'FG004', 'numSubjects': '45'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '7'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Reason not specified', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}, {'title': '104-week Open-Label Extension Period', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'comment': 'These participants were initially randomized to receive ruxolitinib cream 0.5% QD on Day 1 and entered the Extension Period.', 'groupId': 'FG002', 'numSubjects': '28'}, {'comment': 'These participants were initially randomized to receive ruxolitinib cream 1.5% QD on Day 1 and entered the Extension Period.', 'groupId': 'FG003', 'numSubjects': '21'}, {'comment': 'These participants were initially randomized to receive ruxolitinib cream 1.5% BID on Day 1 and entered the Extension Period.', 'groupId': 'FG004', 'numSubjects': '28'}, {'comment': 'These participants were initially randomized to receive ruxolitinib cream 0.15% QD or vehicle on Day 1.', 'groupId': 'FG005', 'numSubjects': '46'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '11'}, {'groupId': 'FG003', 'numSubjects': '8'}, {'groupId': 'FG004', 'numSubjects': '12'}, {'groupId': 'FG005', 'numSubjects': '23'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '17'}, {'groupId': 'FG003', 'numSubjects': '13'}, {'groupId': 'FG004', 'numSubjects': '16'}, {'groupId': 'FG005', 'numSubjects': '23'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '6'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Pregnancy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '9'}, {'groupId': 'FG003', 'numSubjects': '10'}, {'groupId': 'FG004', 'numSubjects': '13'}, {'groupId': 'FG005', 'numSubjects': '15'}]}, {'type': 'Other Reason not specified', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'A total of 157 participants with vitiligo were treated at 26 study centers in the United States.', 'preAssignmentDetails': '157 participants were randomized to receive 1 of 4 dose strengths of ruxolitinib cream (0.15% once daily \\[QD\\], 0.5% QD, 1.5% QD, 1.5% twice daily \\[BID\\]) or vehicle during the 24-week, double-blind (DB), vehicle-controlled treatment period. After the DB period, 11 participants remained on 0.15% QD, and 42 participants who met criteria were re-randomized to 1 of the 3 higher active blinded treatment groups. All other participants remained on the same treatment regimen through Week 52.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'BG000'}, {'value': '31', 'groupId': 'BG001'}, {'value': '31', 'groupId': 'BG002'}, {'value': '30', 'groupId': 'BG003'}, {'value': '33', 'groupId': 'BG004'}, {'value': '157', 'groupId': 'BG005'}]}], 'groups': [{'id': 'BG000', 'title': 'Vehicle Twice Daily (BID)', 'description': 'Vehicle cream BID for 24 weeks (double-blind, vehicle-controlled treatment period), followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% once daily (QD), or 0.5% QD for Weeks 24 to 52 (continued double-blind treatment period), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'BG001', 'title': 'Ruxolitinib Cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 24 or 52 weeks. Those who did not achieve a 25% improvement in F-VASI score were re-randomized to receive ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening), 1.5% QD in the morning (vehicle cream in the evening), or 1.5% BID for Weeks 24 to 52 (continued double-blind treatment period). All participants applied ruxolitinib cream 1.5% BID in the 104-week open-label extension period.'}, {'id': 'BG002', 'title': 'Ruxolitinib Cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'BG003', 'title': 'Ruxolitinib Cream 1.5% QD', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'BG004', 'title': 'Ruxolitinib Cream 1.5% BID', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks (combined vehicle-controlled and continued double-blind periods), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension period.'}, {'id': 'BG005', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '46.3', 'spread': '13.11', 'groupId': 'BG000'}, {'value': '45.1', 'spread': '11.46', 'groupId': 'BG001'}, {'value': '53.8', 'spread': '14.34', 'groupId': 'BG002'}, {'value': '46.7', 'spread': '11.73', 'groupId': 'BG003'}, {'value': '49.5', 'spread': '12.28', 'groupId': 'BG004'}, {'value': '48.3', 'spread': '12.85', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '18', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '19', 'groupId': 'BG003'}, {'value': '15', 'groupId': 'BG004'}, {'value': '84', 'groupId': 'BG005'}]}, {'title': 'Male', 'measurements': [{'value': '12', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}, {'value': '11', 'groupId': 'BG003'}, {'value': '18', 'groupId': 'BG004'}, {'value': '73', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Hispanic or Latino', 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '33', 'groupId': 'BG005'}]}]}, {'title': 'Not Hispanic or Latino', 'categories': [{'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '22', 'groupId': 'BG001'}, {'value': '23', 'groupId': 'BG002'}, {'value': '21', 'groupId': 'BG003'}, {'value': '27', 'groupId': 'BG004'}, {'value': '114', 'groupId': 'BG005'}]}]}, {'title': 'Not Reported', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '7', 'groupId': 'BG005'}]}]}, {'title': 'Unknown', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}, {'title': 'Captured as "Other"', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'White/Caucasian', 'categories': [{'measurements': [{'value': '26', 'groupId': 'BG000'}, {'value': '29', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '23', 'groupId': 'BG003'}, {'value': '29', 'groupId': 'BG004'}, {'value': '132', 'groupId': 'BG005'}]}]}, {'title': 'Black/African-American', 'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '14', 'groupId': 'BG005'}]}]}, {'title': 'Asian', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '5', 'groupId': 'BG005'}]}]}, {'title': 'Mexican', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}, {'title': 'Nigerian/West African', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}, {'title': 'Cuban', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}, {'title': 'Spanish', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}, {'title': 'Hispanic', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}, {'title': 'Caucasian, Black, and Asian', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Facial Body Surface Area (F-BSA) Involvement', 'classes': [{'categories': [{'measurements': [{'value': '1.44', 'spread': '0.838', 'groupId': 'BG000'}, {'value': '1.35', 'spread': '0.858', 'groupId': 'BG001'}, {'value': '1.40', 'spread': '0.760', 'groupId': 'BG002'}, {'value': '1.67', 'spread': '0.953', 'groupId': 'BG003'}, {'value': '1.55', 'spread': '0.892', 'groupId': 'BG004'}, {'value': '1.48', 'spread': '0.858', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'description': 'F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids.', 'unitOfMeasure': 'percentage of facial surface area', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Total Body Surface Area (T-BSA) Involvement', 'classes': [{'categories': [{'measurements': [{'value': '23.54', 'spread': '20.960', 'groupId': 'BG000'}, {'value': '17.56', 'spread': '10.925', 'groupId': 'BG001'}, {'value': '22.96', 'spread': '21.449', 'groupId': 'BG002'}, {'value': '24.81', 'spread': '20.056', 'groupId': 'BG003'}, {'value': '21.46', 'spread': '16.820', 'groupId': 'BG004'}, {'value': '22.05', 'spread': '18.377', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'description': 'T-BSA involvement was the proportion of the body surface area with vitiligo. The body was divided into the following 6 separate and mutually exclusive sites: (1) head/neck, (2) hands, (3) upper extremities (excluding hands), (4) trunk, (5) lower extremities (excluding feet), and (6) feet.', 'unitOfMeasure': 'percentage of total body surface area', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Face Vitiligo Area Scoring Index (F-VASI)', 'classes': [{'categories': [{'measurements': [{'value': '1.21', 'spread': '0.845', 'groupId': 'BG000'}, {'value': '1.19', 'spread': '0.754', 'groupId': 'BG001'}, {'value': '1.22', 'spread': '0.705', 'groupId': 'BG002'}, {'value': '1.45', 'spread': '0.980', 'groupId': 'BG003'}, {'value': '1.26', 'spread': '0.807', 'groupId': 'BG004'}, {'value': '1.26', 'spread': '0.817', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'description': 'F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), 100% (no pigment). F-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each facial site and summing all values (range: 0-3; lower scores indicate increased improvement).', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Total Body Vitiligo Area Scoring Index (T-VASI)', 'classes': [{'categories': [{'measurements': [{'value': '19.40', 'spread': '18.512', 'groupId': 'BG000'}, {'value': '14.57', 'spread': '9.049', 'groupId': 'BG001'}, {'value': '18.43', 'spread': '15.363', 'groupId': 'BG002'}, {'value': '20.55', 'spread': '18.488', 'groupId': 'BG003'}, {'value': '16.94', 'spread': '14.256', 'groupId': 'BG004'}, {'value': '17.96', 'spread': '15.451', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'description': 'T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), 100% (no pigment). T-VASI was derived by multiplying vitiligo involvement values by the percentage of affected skin for each site and summing all values (range: 0-100; lower scores=increased improvement).', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'STANDARD_DEVIATION'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2019-08-01', 'size': 2978849, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2021-09-09T16:39', 'hasProtocol': True}, {'date': '2017-06-28', 'size': 1474453, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2021-09-09T16:39', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR'], 'maskingDescription': 'Double Blind'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 157}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-06-07', 'type': 'ACTUAL'}, 'statusVerifiedDate': '2022-10', 'dispFirstSubmitDate': '2019-09-10', 'completionDateStruct': {'date': '2021-09-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-10-25', 'studyFirstSubmitDate': '2017-03-28', 'dispFirstSubmitQcDate': '2021-12-08', 'resultsFirstSubmitDate': '2021-09-09', 'studyFirstSubmitQcDate': '2017-03-28', 'dispFirstPostDateStruct': {'date': '2021-12-10', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2022-11-17', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-12-08', 'studyFirstPostDateStruct': {'date': '2017-04-04', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2021-12-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-09-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index Score (F-VASI50) Compared With Participants Treated With Vehicle at Week 24', 'timeFrame': 'Baseline; Week 24', 'description': "An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \\[BSA\\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement)."}], 'secondaryOutcomes': [{'measure': "Percentage of Participants Who Achieved a Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) of Clear or Almost Clear", 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.'}, {'measure': 'Percentage of Participants Who Achieved a ≥ 50% Improvement From Baseline in Full Body Assessment of Vitiligo Area and Severity Index (T-VASI) at Week 52', 'timeFrame': 'Baseline; Week 52', 'description': 'T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).'}, {'measure': 'Dose Response on Percentage Change From Baseline in F-VASI', 'timeFrame': 'up to 156 weeks'}, {'measure': 'Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Grade 3 or Higher TEAE up to Week 24', 'timeFrame': 'up to 24 weeks', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.'}, {'measure': 'Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE up to Week 52', 'timeFrame': 'up to 52 weeks', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.'}, {'measure': 'Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 24 to Week 52', 'timeFrame': 'Week 24 to Week 52', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.'}, {'measure': 'Number of Participants Who Applied Ruxolitinib 1.5% Cream BID Throughout Study Participation With Any TEAE and Any Grade 3 or Higher TEAE', 'timeFrame': 'up to Week 156', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.'}, {'measure': 'Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 52 to Week 156', 'timeFrame': 'Week 52 to Week 156', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.'}, {'measure': 'Mean Change From Baseline in F-VASI Score at Week 24', 'timeFrame': 'Baseline; Week 24', 'description': "F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value."}, {'measure': 'Mean Change From Baseline in F-VASI Score at Weeks 52, 104, and 156', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value."}, {'measure': 'Percentage Change From Baseline in F-VASI Score at Week 24', 'timeFrame': 'Baseline; Week 24', 'description': "F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100."}, {'measure': 'Percentage Change From Baseline in F-VASI Score at Weeks 52, 104, and 156', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100."}, {'measure': 'Percentage of Participants Who Achieved an F-VASI50 at Weeks 52, 104, and 156', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement)."}, {'measure': 'Percentage Change From Baseline in F-BSA Repigmentation at Week 24', 'timeFrame': 'Baseline; Week 24', 'description': 'F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant\'s entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant\'s thumb was considered as 0.1% BSA. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.'}, {'measure': 'Percentage Change From Baseline in F-BSA Repigmentation at Weeks 52, 104, and 156', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': 'F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant\'s entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant\'s thumb was considered as 0.1% BSA. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100.'}, {'measure': 'Percentage Change From Baseline in T-BSA Repigmentation at Week 24', 'timeFrame': 'Baseline; Week 24', 'description': "T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100."}, {'measure': 'Percentage Change From Baseline in T-BSA Repigmentation at Weeks 52, 104, and 156', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\\[post-Baseline value minus Baseline value\\]/Baseline value) X 100."}, {'measure': 'Mean Change From Baseline in T-VASI Score at Week 24', 'timeFrame': 'Baseline; Week 24', 'description': "T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline (BL) was calculated as the post-BL value minus the BL value."}, {'measure': 'Mean Change From Baseline in T-VASI Score at Weeks 52, 104, and 156', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value."}, {'measure': 'Percentage Change From Baseline in T-VASI Score at Week 24', 'timeFrame': 'Baseline; Week 24', 'description': "T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement)."}, {'measure': 'Percentage Change From Baseline in T-VASI Score at Weeks 52, 104, and 156', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': "T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement)."}, {'measure': 'Mean Change From Baseline in Vitiligo European Task Force (VETF) Scale Scores at Week 24: Total Spreading', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': 'Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Spreading', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': 'Mean Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': 'Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': 'Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': 'Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': 'Mean Change From Baseline in VETF Scale Scores at Week 24: Total Staging', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': 'Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': 'Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Staging', 'timeFrame': 'Baseline; Week 24', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': 'Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging', 'timeFrame': 'Baseline; Weeks 52 and 104', 'description': 'The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).'}, {'measure': "Percentage of Participants in Each Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) Category at Week 24", 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.'}, {'measure': 'Percentage of Participants in Each Facial Assessment of the PhGVA (F-PhGVA) Category at Weeks 52, 104 and 156', 'timeFrame': 'Weeks 52, 104, and 156', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.'}, {'measure': 'Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Week 24', 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.'}, {'measure': 'Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Weeks 52, 104 and 156', 'timeFrame': 'Weeks 52, 104, and 156', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening.'}, {'measure': "Percentage of Participants in Each Facial Assessment of the Patient's Global Vitiligo Assessment (F-PaGVA) Category at Week 24", 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.'}, {'measure': 'Percentage of Participants in Each Facial Assessment of the PaGVA (F-PaGVA) Category at Weeks 52, 104, and 156', 'timeFrame': 'Weeks 52, 104, and 156', 'description': 'The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.'}, {'measure': 'Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Week 24', 'timeFrame': 'Week 24', 'description': 'The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.'}, {'measure': 'Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Weeks 52, 104, and 156', 'timeFrame': 'Weeks 52, 104, and 156', 'description': 'The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.'}, {'measure': 'Percentage of Participants in Each Patient Global Impression of Change for Vitiligo (PaGIC-V) Category at Week 24', 'timeFrame': 'Baseline; Week 24', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.'}, {'measure': 'Percentage of Participants in Each PaGIC-V Category at Weeks 52, 104, and 156', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.'}, {'measure': 'Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Week 24', 'timeFrame': 'Baseline; Week 24', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.'}, {'measure': 'Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Weeks 52, 104, and 156', 'timeFrame': 'Baseline; Weeks 52, 104, and 156', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.'}, {'measure': 'Time to Achieve an F-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the F-VASI50 Score', 'timeFrame': 'up to 52 weeks', 'description': "An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement)."}, {'measure': 'Time to Achieve a T-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the T-VASI50 Score', 'timeFrame': 'up to 52 weeks', 'description': 'A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI. T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).'}, {'measure': 'Time to Achieve an F-PhGVA of Clear or Almost Clear', 'timeFrame': 'up to 52 weeks', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening. Time to achieve an F-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the F-PhGVA score.'}, {'measure': 'Time to Achieve an T-PhGVA of Clear or Almost Clear', 'timeFrame': 'up to 52 weeks', 'description': 'The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \\< 30% hair whitening); 4=severe disease, complete depigmentation plus \\> 30% hair whitening. Time to achieve a T-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the T-PhGVA score.'}, {'measure': 'Time to Achieve a PaGIC-V of Very Much Improved or Much Improved', 'timeFrame': 'up to 52 weeks', 'description': 'The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant\'s treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you\'ve received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse. Time to achieve a PaGIC-V response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the PaGIC-V score.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Vitiligo', 'depigmenting disorder', 'topical JAK inhibitor'], 'conditions': ['Vitiligo']}, 'referencesModule': {'references': [{'pmid': '37840766', 'type': 'DERIVED', 'citation': 'Howell MD, Kuo FI, Rumberger B, Boarder E, Sun K, Butler K, Harris JE, Grimes P, Rosmarin D. Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream. JID Innov. 2023 Sep 13;3(6):100230. doi: 10.1016/j.xjidi.2023.100230. eCollection 2023 Nov.'}, {'pmid': '32653055', 'type': 'DERIVED', 'citation': 'Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 Jul 11;396(10244):110-120. doi: 10.1016/S0140-6736(20)30609-7.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Clinical diagnosis of vitiligo.\n* Vitiligo with depigmented areas including:\n\n * at least 0.5% of the total body surface area (BSA) on the face (0.5% BSA is approximately equal to the area of the participant's palm \\[without digits\\]) AND\n * at least 3% of the total BSA on nonfacial areas (3% BSA is approximately equal to the area of 3 of the participant's handprints \\[palm plus 5 digits\\]).\n* Participants who agree to discontinue all agents used to treat vitiligo from screening through the final follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.\n\nExclusion Criteria:\n\n* Conditions at baseline that would interfere with evaluation of vitiligo.\n* Participants who are receiving any kind of phototherapy, including tanning beds.\n* Participants with other dermatologic disease besides vitiligo whose presence or treatments could complicate the assessment of repigmentation.\n* Participants who have used skin bleaching treatments for past treatment of vitiligo or other pigmented areas.\n* Participants who have received any of the following treatments within the minimum specified timeframes.\n\n * Use of any biologic, investigational, or experimental therapy or procedure for vitiligo within 12 weeks or 5 half-lives (whichever is longer) of screening.\n * Use of laser or light-based vitiligo treatments, including tanning beds, within 8 weeks of screening.\n * Use of immunomodulating oral or systemic medications (eg, corticosteroids, methotrexate, cyclosporine) or topical treatments that may affect vitiligo (eg, corticosteroids, tacrolimus/pimecrolimus, retinoids) within 4 weeks of screening.\n* Use of any prior and concomitant therapy not listed above that may interfere with the objective of the study as per discretion of the investigator, including drugs that cause photosensitivity or skin pigmentation (eg, antibiotics such as tetracyclines, antifungals) within 8 weeks of screening.\n* Participants with a clinically significant abnormal thyroid-stimulating hormone or free T4 at screening.\n* Participants with protocol-defined cytopenias at screening\n* Participants with severely impaired liver function.\n* Participants with impaired renal function.\n* Participants taking potent systemic cytochrome P450 3A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit.\n* Participants who have previously received JAK inhibitor therapy, systemic or topical."}, 'identificationModule': {'nctId': 'NCT03099304', 'briefTitle': 'A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo', 'organization': {'class': 'INDUSTRY', 'fullName': 'Incyte Corporation'}, 'officialTitle': 'A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo', 'orgStudyIdInfo': {'id': 'INCB 18424-211'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Ruxolitinib cream 1.5% twice daily (BID)', 'description': 'Ruxolitinib cream 1.5% BID for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.', 'interventionNames': ['Drug: Ruxolitinib cream']}, {'type': 'EXPERIMENTAL', 'label': 'Ruxolitinib cream 1.5% once daily (QD)', 'description': 'Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.', 'interventionNames': ['Drug: Ruxolitinib cream', 'Drug: Vehicle cream']}, {'type': 'EXPERIMENTAL', 'label': 'Ruxolitinib cream 0.5% QD', 'description': 'Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.', 'interventionNames': ['Drug: Ruxolitinib cream', 'Drug: Vehicle cream']}, {'type': 'EXPERIMENTAL', 'label': 'Ruxolitinib cream 0.15% QD', 'description': 'Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if \\< 25% improvement in F-VASI score), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.', 'interventionNames': ['Drug: Ruxolitinib cream', 'Drug: Vehicle cream']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Vehicle BID', 'description': 'Vehicle cream BID for 24 weeks, followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.', 'interventionNames': ['Drug: Ruxolitinib cream', 'Drug: Vehicle cream']}], 'interventions': [{'name': 'Ruxolitinib cream', 'type': 'DRUG', 'otherNames': ['INCB018424 cream'], 'description': 'Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.', 'armGroupLabels': ['Ruxolitinib cream 0.15% QD', 'Ruxolitinib cream 0.5% QD', 'Ruxolitinib cream 1.5% once daily (QD)', 'Ruxolitinib cream 1.5% twice daily (BID)', 'Vehicle BID']}, {'name': 'Vehicle cream', 'type': 'DRUG', 'description': 'Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.', 'armGroupLabels': ['Ruxolitinib cream 0.15% QD', 'Ruxolitinib cream 0.5% QD', 'Ruxolitinib cream 1.5% once daily (QD)', 'Vehicle BID']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35233', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'UNIVERSITY OF ALABAMA AT BIRMINGHAM (UAB), 1802 6th Ave S', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '71913', 'city': 'Hot Springs', 'state': 'Arkansas', 'country': 'United States', 'facility': 'BURKE PHARMACEUTICAL RESEARCH LLC, 3633 Central Ave', 'geoPoint': {'lat': 34.5037, 'lon': -93.05518}}, {'zip': '72758', 'city': 'Rogers', 'state': 'Arkansas', 'country': 'United States', 'facility': 'NORTHWEST AR CLINICAL TRIALS CENTER, PLLC/HULL DERMATOLOGY, PA, 500 S 52nd Street', 'geoPoint': {'lat': 36.33202, 'lon': -94.11854}}, {'zip': '90036', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'THE VITILIGO & PIGMENTATION INSTITUE OF SOUTHERN CALIFORNIA, 5670 Wilshire Boulevard', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90045', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'DERMATOLOGY RESEARCH ASSOCIATES- LOS ANGELES, 8930 S Sepulveda Blvd', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92056', 'city': 'Oceanside', 'state': 'California', 'country': 'United States', 'facility': 'DERMATOLOGY SPECIALISTS, 3629 Vista Way', 'geoPoint': {'lat': 33.19587, 'lon': -117.37948}}, {'zip': '06810', 'city': 'Danbury', 'state': 'Connecticut', 'country': 'United States', 'facility': 'CLINICAL RESEARCH CENTER OF CT, 27 Hospital Avenue', 'geoPoint': {'lat': 41.39482, 'lon': -73.45401}}, {'zip': '32174', 'city': 'Ormond Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'LEAVITT MEDICAL ASSOCIATES OF FLORIDA INC/ AMERIDERM RESEARCH, 725 W Granada Blvd', 'geoPoint': {'lat': 29.28581, 'lon': -81.05589}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'EMORY UNIVERSITY, 1525 Clifton Road', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'NORTHWESTERN UNIVERSITY, 676 N Saint Clair', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '46256', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'DAWES FRETZIN CLINICAL RESEARCH GROUP, 8103 Clearvista Parkway', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '47150', 'city': 'New Albany', 'state': 'Indiana', 'country': 'United States', 'facility': 'DS RESEARCH, 2241 Green Valley Road', 'geoPoint': {'lat': 38.28562, 'lon': -85.82413}}, {'zip': '70112', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'TULANE UNIVERSITY, 1415 Tulane Avenue', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '02111', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Tufts Medical Center, 260 Tremont Street', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '01605', 'city': 'Worcester', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'UNIVERSITY OF MASSACHUESETTS, 364 Plantation Street', 'geoPoint': {'lat': 42.26259, 'lon': -71.80229}}, {'zip': '48059', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'HAMZAVI DERMATOLOGY, 3031 W Grand Blvd', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '63141', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY, 969 N. Mason Road', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '03801', 'city': 'Portsmouth', 'state': 'New Hampshire', 'country': 'United States', 'facility': 'ACTIVMED PRACTICES & RESEARCH, INC, 110 Corporate Drive', 'geoPoint': {'lat': 43.07704, 'lon': -70.75766}}, {'zip': '11209', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI MEDICAL CENTER- DERMATOLOGY ASSOCIATES, 5 E 98th Street', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '27157', 'city': 'Winston-Salem', 'state': 'North Carolina', 'country': 'United States', 'facility': 'WAKE FOREST UNIVERSITY HEALTH SCIENCES, Medical Center Boulevard', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '73071', 'city': 'Norman', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'CENTRAL SOONER RESEARCH, 900 N Porter Ave', 'geoPoint': {'lat': 35.22257, 'lon': -97.43948}}, {'zip': '02903', 'city': 'Providence', 'state': 'Rhode Island', 'country': 'United States', 'facility': 'RHODE ISLAND HOSPITAL, 593 Eddy Street', 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}}, {'zip': '76011', 'city': 'Arlington', 'state': 'Texas', 'country': 'United States', 'facility': 'ARLINGTON RESEARCH CENTER, INC., 711 East Lamar Boulevard', 'geoPoint': {'lat': 32.73569, 'lon': -97.10807}}, {'zip': '75246', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'MENTER DERMATOLOGY RESEARCH INSTITUTE, 3900 Junius Street', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, DEPARTMENT OF DERMATOLOGY, 5323 Harry Hines Blvd', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'THE DERMATOLOGY AND LASER CENTER OF SAN ANTONIO, 7810 Louis Pasteur', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}], 'overallOfficials': [{'name': 'Kathleen Butler, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Incyte Corporation'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Incyte Corporation', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}